Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Core Points - A class action has been filed against Neumora Therapeutics, Inc. on behalf of investors who purchased shares during the IPO on September 15, 2023 [1] - The allegations claim that Neumora misled investors regarding the prospects of its flagship candidate, Navacaprant, for treating major depressive disorder (MDD) [2][3] - Following the announcement of disappointing results from the KOASTAL-1 study on January 2, 2025, Neumora's stock price plummeted from $17 to$1.91, representing an 88.7% decline [3] Allegations - The Offering Documents allegedly failed to disclose critical information about Navacaprant's Phase Two Trial, including amendments to inclusion criteria and inadequate data regarding patient demographics [2] - The complaint highlights that the Phase Two Trials did not provide sufficient data to predict the outcomes of the subsequent KOASTAL-1 study [2] Stock Performance - Neumora's common stock has seen a significant decline since the IPO, dropping from an initial price of $17 per share to$1.91 per share by February 5, 2025 [3] Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file by April 7, 2025 [4] - The representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]